In addition, a phase I/II trial of pembrolizumab in combination with the HDAC inhibitor pralatrexate (NCT03598998) and a phase I trial of pembrolizumab in triple combination with pralatrexate and the epigenetic modifier decitabine (NCT03240211) in R/R PTCL are also underway. The gene discussed is HDAC9; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.